Neutralizing and enhancing antibodies against SARS-CoV-2

The high transmissibility and rapid global spread of SARS-CoV-2 since 2019 has led to a huge burden on healthcare worldwide. Anti-SARS-CoV-2 neutralizing antibodies play an important role in not only protecting against infection but also in clearing the virus and are essential to providing long-term...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yafei, Arase, Hisashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720987/
https://www.ncbi.nlm.nih.gov/pubmed/36471381
http://dx.doi.org/10.1186/s41232-022-00233-7
_version_ 1784843668267466752
author Liu, Yafei
Arase, Hisashi
author_facet Liu, Yafei
Arase, Hisashi
author_sort Liu, Yafei
collection PubMed
description The high transmissibility and rapid global spread of SARS-CoV-2 since 2019 has led to a huge burden on healthcare worldwide. Anti-SARS-CoV-2 neutralizing antibodies play an important role in not only protecting against infection but also in clearing the virus and are essential to providing long-term immunity. On the other hand, antibodies against the virus are not always protective. With the emergence of SARS-CoV-2 immune escape variants, vaccine design strategies as well as antibody-mediated therapeutic approaches have become more important. We review some of the findings on SARS-CoV-2 antibodies, focusing on both basic research and clinical applications.
format Online
Article
Text
id pubmed-9720987
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97209872022-12-06 Neutralizing and enhancing antibodies against SARS-CoV-2 Liu, Yafei Arase, Hisashi Inflamm Regen Review The high transmissibility and rapid global spread of SARS-CoV-2 since 2019 has led to a huge burden on healthcare worldwide. Anti-SARS-CoV-2 neutralizing antibodies play an important role in not only protecting against infection but also in clearing the virus and are essential to providing long-term immunity. On the other hand, antibodies against the virus are not always protective. With the emergence of SARS-CoV-2 immune escape variants, vaccine design strategies as well as antibody-mediated therapeutic approaches have become more important. We review some of the findings on SARS-CoV-2 antibodies, focusing on both basic research and clinical applications. BioMed Central 2022-12-05 /pmc/articles/PMC9720987/ /pubmed/36471381 http://dx.doi.org/10.1186/s41232-022-00233-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Liu, Yafei
Arase, Hisashi
Neutralizing and enhancing antibodies against SARS-CoV-2
title Neutralizing and enhancing antibodies against SARS-CoV-2
title_full Neutralizing and enhancing antibodies against SARS-CoV-2
title_fullStr Neutralizing and enhancing antibodies against SARS-CoV-2
title_full_unstemmed Neutralizing and enhancing antibodies against SARS-CoV-2
title_short Neutralizing and enhancing antibodies against SARS-CoV-2
title_sort neutralizing and enhancing antibodies against sars-cov-2
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720987/
https://www.ncbi.nlm.nih.gov/pubmed/36471381
http://dx.doi.org/10.1186/s41232-022-00233-7
work_keys_str_mv AT liuyafei neutralizingandenhancingantibodiesagainstsarscov2
AT arasehisashi neutralizingandenhancingantibodiesagainstsarscov2

Ejemplares similares